Psychiatric & Neurological APIs

psychiatric-neurological-apis

BOC Sciences can provide development services for psychoneurotic APIs. Our neuropsychiatric drug research and development team is led by a number of scientists with rich project experience, each of whom has decades of drug research and development experience and is proficient in the field of nervous system expertise, and can help you solve any drug difficulties in the development phase. The neuropsychiatric drug market is second only to cardiovascular and cerebrovascular drugs, and is the second largest drug field in the world. Currently, our research focuses on neurological and psychiatric diseases and neurodegenerative diseases (Alzheimer's disease, Parkinson's disease). Our goal is to develop innovative neuropsychiatric drugs that lead the world.

What are Neurological Disorders?

The occurrence of mental illness is the result of the combined action of many factors such as physiology, psychology and environment. These diseases mainly occur in the central nervous system, peripheral nervous system and autonomic nervous system, causing functional damage to the brain, and then losing the ability to normally control emotion, cognition, behavior, etc., or appearing dysfunctional. Because the causes of mental illness are complex and varied, it makes the treatment extremely difficult. There are also many types of neuropsychiatric diseases, involving more than 1,000 indications, such as Alzheimer's disease (AD), Parkinson's disease (PD), depression, anxiety, schizophrenia, epilepsy, nervous system infections disease, etc. Neuropsychiatric diseases are diseases with low fatality rate and high disability rate. Neuropsychiatric diseases also often interact with diseases such as cancer and cardiovascular disease, aggravating the disease.

APIs for Neurological Disorders

In the current global drug market for neuropsychiatric diseases, the market share of small molecule drugs far exceeds that of biological drugs, and most of them are original drugs. APIs for the central nervous system refer to chemicals used to treat psychiatric and neurological disorders and can be divided into the following types based on their use.

Antipsychotics: chlorpromazine, haloperidol, olanzapine, risperidone, etc.
Antidepressants: paroxetine, fluoxetine, venlafaxine, sertraline, etc.
Anti-anxiety drugs: lorazepam, alprazolam, sertraline, etc.
Antiepileptic drugs: carbamazepine, gabapentin, etc.

API Development for Neurological Disorders

The development process of Psychiatric & Neurological APIs includes the synthesis of small molecule APIs and formulation optimization services. During the preparation of small molecule APIs, the efficacy of the APIs can be adjusted through continuous optimization, while facilitating the development of the client's project.

Synthesis of Small Molecule APIs

The synthesis of APIs requires the design of the route of preparation according to the customer's requirements and application, and then the selection of a suitable preparation method in order to obtain a high-yield and high-purity product. Then, the purified small molecule APIs are analyzed and validated to ensure that the product obtained by the customer is the target molecule. In addition, the small molecule APIs need to be analyzed for activity to ensure that the products obtained have specific efficacy.

Formulation Optimization of APIs

Formulation optimization of APIs involves adjusting solvents, adjusting the physical and chemical properties of APIs, using solubilizers, permeation enhancers, etc. to improve their solubility and bioavailability. In addition, our technicians need to evaluate the effectiveness of API formulations in terms of long-term stability, suitability, and potency. This process includes testing and evaluating the physicochemical stability, solubility, dissolution, and degradation reactions of pharmaceutical formulations under different conditions.

What Can We Offer?

Biomarker Discovery & Detection

Taking advantage of the in-depth understanding of the pathogenesis of neuropsychiatric diseases, starting from high-quality biobanks, and fully combining the technical advantages of genomics, proteomics and metabolomics, we search for early sensitive biomarkers closely related to the pathogenesis form various body fluids.

Neuropharmacological Research

According to the model of pharmacodynamic response, the characteristics of pharmacokinetics, etc., the appropriate pharmacological experimental method is selected, and it runs through the whole process of new drug research.

Patch Clamp Techniques

Including whole-cell patch-clamp technology for the study of ion channel properties, perforated patch-clamp technology, which can be used in the stage of drug candidate identification and new drug application, as well as in the stage of lead compound discovery.

Our Highlights

Internationally leading R&D capabilities, with R&D laboratories in the United States and China
A wide range of cooperation models, including consulting registration, joint development, technology transfer, etc.
Senior team, more than 20 years of R&D experience

In addition to API development for psychiatry and neurology, we offer featured API and intermediate customization development services for angiotensin receptor blockers (ARBs), hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), tyrosine kinase inhibitors (TKIs) and heparin. If you are interested in our APIs custom development service, please contact us immediately.

Ability